Precision Medicine World Conference 2025 (PMWC 25)
)
PMWC, the Precision Medicine World Conference, is the largest and original annual conference dedicated to precision medicine that brings together recognized leaders, top global researchers and medical professionals, and innovators across healthcare and biotechnology sectors. Oxford Nanopore are sponsoring, exhibiting and presenting at this event.
Register below to save your seat for the Oxford Nanopore presentation Multi-omic characterization of cancer development and progression on Friday, Feb 7.
Please visit us at Booth #A403 if you are able to attend the event.
Session registration
Multi-omic characterization of cancer development and progression
Date: Friday, Feb 7
Time: 9:45 am-10:15 am
Location: Track 4: Multi-omics and wearables for disease intervention and prevention
Insights into how multi-omics captures the molecular complexity of cancer. The role of advanced technologies in identifying actionable biomarkers and pathways. Strategies for overcoming barriers to translating multi-omic research into clinical oncology.
This session brings together trailblazers at the forefront of multi-omic innovation to explore the next wave of breakthroughs in cancer research and precision medicine. Space is limited so be sure to register in advance.
Please contact events@nanoporetech.com with any questions.
Speakers
)
Dr. Kathleen Barnes, SVP, Population and Precision Health, Oxford Nanopore TechnologiesDr. Kathleen C. Barnes is a genetic epidemiologist with expertise in multiple complex lung and inflammatory diseases. For 30 years her population-based studies have focused on ethnically diverse, family-based and independent populations across the Americas, summarized in 230 publications. She has led multiple international multi-omics projects and is a founding PI in the NHLBI Trans-Omics for Precision Medicine (TOPMed) Project. Originally at Johns Hopkins University (1993-2015) then the University of Colorado (2015-present), she has procured 150K biospecimens from her own research laboratory, and high-throughput, cutting edge multi-omics technologies. She is founding Director of the Colorado Center for Personalized Medicine, was SVP of Population Genomics Health at Tempus Labs (2021-2023), and currently leads Population and Precision Health at Oxford Nanopore Technologies, focused on facilitating the transfer of precision health capabilities into clinical application.
)
Orit Rozenblatt-Rosen, PhD, Head of the Cell and Tissue Genomics, GenentechOrit Rozenblatt-Rosen, PhD, is Head of the Cell and Tissue Genomics (CTG) Department at Genentech. CTG aims to develop and apply high resolution methods to characterize cells and tissues to accelerate scientific discovery and help identify targets and next-generation biomarkers for precision medicine treatments for patients. Orit is a pioneer in single-cell genomics technologies and their application to tissues in order to better understand health and disease. Previously, she was the Scientific Director of the Klarman Cell Observatory at the Broad Institute of MIT and Harvard, where she focused on deciphering cellular and tissue circuits. She also co-chairs the standards and technology working group for the Human Cell Atlas consortium.
)
Emily Leproust, CEO & Founder, Twist BioscienceAn early pioneer in the high-throughput synthesis and sequencing of DNA, Emily Leproust, Ph.D., is disrupting markets to enable the exponential growth of DNA-based applications across chemicalsmaterials, diagnostics, therapeutics, food and digital data storage. As CEO and co-founder, she has integrated biosecurity into Twist's processes and offerings while growing Twist from a startup to the leading global company that it is today, leveraging Twist's core technology to expand into new and significant markets and enabling customers to build a better, healthier and more sustainable world with synthetic DNA.
)
Dr. Carol Greider, - - -Nobel Laureate, whose work on telomerase and genomic instability underpins the foundational understanding of cancer biology.
